Information Provided By:
Fly News Breaks for December 13, 2019
SRPT
Dec 13, 2019 | 07:06 EDT
Janney Montgomery Scott analyst Yun Zhong raised Sarepta Therapeutics' price target to $175 from $160 citing the faster than expected FDA approval for Vyondys and management's plan for an immediate U.S. launch. The analyst projects a trajectory in market penetration that is similar to what Exondys 51 achieved in 2017. Further, available dystrophin production data could support an FDA accelerated approval for casimersen by the end of 2020, Zhong tells investors in a research note. The analyst reiterates a Buy rating on Sarepta.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.